Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
AbbVie Inc. announced that the European Commission has approved Rinvoq (Upadacitinib) for the treatment of children with active polyarticular juvenile idiopathic arthritis, aged two years and older.
ABBV - AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
AbbVie rises on new drug approvals
AbbVie's RINVOQ approved for severe alopecia areata